| scholarly article | Q13442814 |
| P50 | author | Ian Andrew Wilson | Q5983280 |
| Andrew B Ward | Q90160109 | ||
| P2860 | cites work | Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs | Q21090520 |
| Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ | Q21090535 | ||
| Structural mechanism of trimeric HIV-1 envelope glycoprotein activation | Q21131394 | ||
| Increasing the potency and breadth of an HIV antibody by using structure-based rational design | Q24631510 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies | Q27644515 | ||
| Molecular architecture of native HIV-1 gp120 trimers | Q27651385 | ||
| Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility | Q27658989 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization | Q27677117 | ||
| Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops | Q27678226 | ||
| Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 | Q27678306 | ||
| Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 | Q27678312 | ||
| Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies | Q27679353 | ||
| Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy | Q27680442 | ||
| Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer | Q27680496 | ||
| Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer | Q27680497 | ||
| Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign | Q27681806 | ||
| Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike | Q27683540 | ||
| Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers | Q27683553 | ||
| Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization | Q27684578 | ||
| Atomic structure of the ectodomain from HIV-1 gp41 | Q27738021 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies | Q28299280 | ||
| Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy | Q28654490 | ||
| Distribution and three-dimensional structure of AIDS virus envelope spikes | Q29617562 | ||
| Structure of a V3-containing HIV-1 gp120 core | Q29619014 | ||
| MALDI-MS/MS with traveling wave ion mobility for the structural analysis of N-linked glycans | Q31095515 | ||
| Rational antibody-based HIV-1 vaccine design: current approaches and future directions | Q33937285 | ||
| The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. | Q33999756 | ||
| Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. | Q34361680 | ||
| Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface | Q34473958 | ||
| CD4-induced activation in a soluble HIV-1 Env trimer | Q34510675 | ||
| Structural evolution of glycan recognition by a family of potent HIV antibodies | Q34782382 | ||
| Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120 | Q34885869 | ||
| Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin | Q34999293 | ||
| Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions | Q35006601 | ||
| Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes | Q35034268 | ||
| Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures | Q35105223 | ||
| Structure and immune recognition of trimeric pre-fusion HIV-1 Env. | Q35142291 | ||
| HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins | Q36276274 | ||
| Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. | Q36692987 | ||
| Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies | Q36750045 | ||
| N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies | Q37010852 | ||
| Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers | Q37123501 | ||
| Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein | Q37123584 | ||
| Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation | Q37318042 | ||
| Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain | Q37333789 | ||
| Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers | Q39001126 | ||
| Ion mobility mass spectrometry for extracting spectra of N-glycans directly from incubation mixtures following glycan release: application to glycans from engineered glycoforms of intact, folded HIV gp120. | Q39562642 | ||
| A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure | Q39588870 | ||
| Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis | Q40397998 | ||
| Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. | Q42215329 | ||
| Travelling wave ion mobility and negative ion fragmentation for the structural determination of N-linked glycans | Q45144924 | ||
| P433 | issue | 2 | |
| P921 | main subject | HIV | Q15787 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 101-107 | |
| P577 | publication date | 2015-01-16 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Trends in Biochemical Sciences | Q1565711 |
| P1476 | title | Insights into the trimeric HIV-1 envelope glycoprotein structure | |
| P478 | volume | 40 |
| Q35925858 | A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS |
| Q41037927 | Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. |
| Q26991572 | Antibody responses to envelope glycoproteins in HIV-1 infection |
| Q39108751 | Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development |
| Q37145901 | Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency |
| Q33592852 | Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System |
| Q40679052 | Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design |
| Q58693500 | CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation |
| Q28263655 | Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope |
| Q39186163 | Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies |
| Q33786447 | Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller |
| Q28554907 | Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene |
| Q40476608 | Determinants of HIV-1 broadly neutralizing antibody induction. |
| Q58763247 | Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers |
| Q92932198 | Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements |
| Q26772129 | Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion |
| Q28828700 | Functional organization of the HIV lipid envelope |
| Q38992744 | Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. |
| Q53689028 | Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. |
| Q64099047 | Glycopeptides and -Mimetics to Detect, Monitor and Inhibit Bacterial and Viral Infections: Recent Advances and Perspectives |
| Q26746070 | HIV Genome-Wide Protein Associations: a Review of 30 Years of Research |
| Q37593177 | Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins |
| Q36736610 | Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody |
| Q41447893 | Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers |
| Q33557844 | Lessons learned from human HIV vaccine trials |
| Q40080000 | Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins |
| Q53695792 | Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11. |
| Q36121053 | Morphology and ultrastructure of retrovirus particles. |
| Q55347049 | Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. |
| Q36736597 | Native Conformation and Canonical Disulfide Bond Formation Are Interlinked Properties of HIV-1 Env Glycoproteins |
| Q37619134 | Natural infection as a blueprint for rational HIV vaccine design |
| Q38748193 | New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. |
| Q64080897 | Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus |
| Q28087528 | Protein Crystallography in Vaccine Research and Development |
| Q37584635 | Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. |
| Q36811996 | Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies |
| Q37448281 | Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits |
| Q39206970 | Role of germinal centers for the induction of broadly-reactive memory B cells |
| Q40076041 | Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers |
| Q36132706 | Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. |
| Q52334297 | Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection |
| Q91711152 | Structural topology defines protective CD8+ T cell epitopes in the HIV proteome |
| Q38291748 | Structure and Glycan Binding of a New Cyanovirin-N Homolog |
| Q54209542 | Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. |
| Q47560170 | Targeted Elimination of Immunodominant B Cells Drives the Germinal Center Reaction toward Subdominant Epitopes |
| Q26786540 | The HIV glycan shield as a target for broadly neutralizing antibodies |
| Q39108789 | The HIV-1 envelope glycoprotein structure: nailing down a moving target |
| Q40231057 | The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans |
| Q40198060 | Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop |
| Q40346058 | What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise |
Search more.